CN110545822A - 药剂、组合物及其相关方法 - Google Patents

药剂、组合物及其相关方法 Download PDF

Info

Publication number
CN110545822A
CN110545822A CN201880027339.7A CN201880027339A CN110545822A CN 110545822 A CN110545822 A CN 110545822A CN 201880027339 A CN201880027339 A CN 201880027339A CN 110545822 A CN110545822 A CN 110545822A
Authority
CN
China
Prior art keywords
compound
insulin
glucose
mice
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880027339.7A
Other languages
English (en)
Chinese (zh)
Inventor
Z-J·蓝
R·鲍尔
A·扬尼库里斯
T·R·耶拉姆雷迪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
All-Tech Co
Original Assignee
All-Tech Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by All-Tech Co filed Critical All-Tech Co
Priority to CN202510741418.6A priority Critical patent/CN120647702A/zh
Publication of CN110545822A publication Critical patent/CN110545822A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CN201880027339.7A 2017-05-19 2018-05-01 药剂、组合物及其相关方法 Pending CN110545822A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202510741418.6A CN120647702A (zh) 2017-05-19 2018-05-01 药剂、组合物及其相关方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762508730P 2017-05-19 2017-05-19
US62/508,730 2017-05-19
PCT/US2018/030371 WO2018212980A1 (en) 2017-05-19 2018-05-01 Pharmaceutical agents, compositions, and methods relating thereto

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202510741418.6A Division CN120647702A (zh) 2017-05-19 2018-05-01 药剂、组合物及其相关方法

Publications (1)

Publication Number Publication Date
CN110545822A true CN110545822A (zh) 2019-12-06

Family

ID=64274560

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201880027339.7A Pending CN110545822A (zh) 2017-05-19 2018-05-01 药剂、组合物及其相关方法
CN202510741418.6A Pending CN120647702A (zh) 2017-05-19 2018-05-01 药剂、组合物及其相关方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202510741418.6A Pending CN120647702A (zh) 2017-05-19 2018-05-01 药剂、组合物及其相关方法

Country Status (10)

Country Link
US (2) US11014954B2 (https=)
EP (1) EP3624809A4 (https=)
JP (1) JP7224303B2 (https=)
CN (2) CN110545822A (https=)
AU (1) AU2018269403B2 (https=)
CA (1) CA3061893A1 (https=)
RU (1) RU2765286C2 (https=)
SA (1) SA519410561B1 (https=)
SG (1) SG11201909932YA (https=)
WO (1) WO2018212980A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018269403B2 (en) 2017-05-19 2025-03-27 Alltech, Inc. Pharmaceutical agents, compositions, and methods relating thereto

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030055016A1 (en) * 2001-03-22 2003-03-20 Zhen Huang Synthesis of selenium-derivatized nucleosides, nucleotides, phosphoramidites, triphosphates and nucleic acids
US20090137520A1 (en) * 2005-10-13 2009-05-28 Elfatih Elzein A1 adenosine receptor agonists
CN106456658A (zh) * 2014-03-14 2017-02-22 全技术公司 硒有机化合物的组合物和其使用方法
WO2017048252A1 (en) * 2015-09-15 2017-03-23 Alltech, Inc. Compositions of selenoorganic compounds and methods of use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030078232A1 (en) 2001-08-08 2003-04-24 Elfatih Elzein Adenosine receptor A3 agonists
EP1652519A1 (en) 2004-10-28 2006-05-03 Tamie Nasu Seleniferous composition for producing antioxidase in vivo
US20060198906A1 (en) 2005-03-07 2006-09-07 Sami Labs Limited Compositions and Method to Increase Serum Levels of HDL cholesterol and Lower the Risk of Cardiovascular Disease
US20070077238A1 (en) 2005-10-04 2007-04-05 Teo Alex Y Production of organic and inorganic selenium compounds by lactic acid bacteria
WO2009032057A2 (en) 2007-08-29 2009-03-12 Adam Lubin Method for the selective therapy of disease
WO2013151975A1 (en) 2012-04-02 2013-10-10 Northeastern University Compositions and methods for the inhibition of methyltransferases
US9833486B2 (en) 2013-03-15 2017-12-05 Alltech, Inc. Compositions comprising selenium and use of same for the treatment and prevention of disease or conditions associated with mitochondrial dysfunction
US20160090397A1 (en) 2014-09-30 2016-03-31 Northeastern University Se-Adenosyl-L-Selenohomocysteine Selenoxide As A Modulator Of Methyltransferase And Other Activities
AU2018269403B2 (en) 2017-05-19 2025-03-27 Alltech, Inc. Pharmaceutical agents, compositions, and methods relating thereto

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030055016A1 (en) * 2001-03-22 2003-03-20 Zhen Huang Synthesis of selenium-derivatized nucleosides, nucleotides, phosphoramidites, triphosphates and nucleic acids
US20090137520A1 (en) * 2005-10-13 2009-05-28 Elfatih Elzein A1 adenosine receptor agonists
CN106456658A (zh) * 2014-03-14 2017-02-22 全技术公司 硒有机化合物的组合物和其使用方法
WO2017048252A1 (en) * 2015-09-15 2017-03-23 Alltech, Inc. Compositions of selenoorganic compounds and methods of use thereof

Also Published As

Publication number Publication date
RU2765286C2 (ru) 2022-01-28
SG11201909932YA (en) 2019-11-28
JP7224303B2 (ja) 2023-02-17
BR112019022918A2 (pt) 2020-05-26
JP2020520904A (ja) 2020-07-16
US20200123191A1 (en) 2020-04-23
CA3061893A1 (en) 2018-11-22
US20210238216A1 (en) 2021-08-05
NZ758538A (en) 2025-08-29
WO2018212980A1 (en) 2018-11-22
AU2018269403B2 (en) 2025-03-27
US11613552B2 (en) 2023-03-28
RU2019134865A3 (https=) 2021-06-30
US11014954B2 (en) 2021-05-25
SA519410561B1 (ar) 2024-03-06
CN120647702A (zh) 2025-09-16
EP3624809A1 (en) 2020-03-25
RU2019134865A (ru) 2021-06-21
AU2018269403A1 (en) 2019-11-14
EP3624809A4 (en) 2021-03-03

Similar Documents

Publication Publication Date Title
US11673873B2 (en) Apelin receptor agonists and methods of use thereof
JP7009053B2 (ja) 有機セレン化合物の組成物およびその使用方法
IL139862A (en) History of thiazolidine or pyroladine as effects of dipheptidyl peptides IV and pharmaceutical preparations containing them
JP2022501331A (ja) 少なくとも１つのグリシン又はその誘導体と、少なくとも１つのｎ−アセチルシステイン又はその誘導体と、少なくとも１つのニコチンアミドリボシド又はｎａｄ＋前駆体と、を使用する組成物及び方法
US20230037225A1 (en) SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS APELIN RECEPTOR AGONISTS
EP3990021A1 (en) Inhibition of dipeptide repeat proteins
US20070244108A1 (en) Phenylsulfonamide Derivatives for Use as 11-Beta-Hydroxysteroid Dehydrogenase Inhibitors
US20220313702A1 (en) Oxathiazin compounds for inhibiting gapdh
US11613552B2 (en) Pharmaceutical agents, compositions, and methods relating thereto
JP2003519660A (ja) 耐糖能に影響を与える薬剤を調製するための、環状エーテルの使用
US20050119197A1 (en) Naadp analogues for modulating t-cell activity
Kim et al. Enhancing effect of indirubin derivatives on 1, 25-dihydroxyvitamin D3-and all-trans retinoic acid-induced differentiation of HL-60 leukemia cells
HK40017181A (en) Pharmaceutical agents, compositions, and methods relating thereto
CN114521142B (zh) 用于抑制和/或治疗神经退行性疾病和/或其临床病症的组合物和方法
US20250009692A1 (en) Micronutrient composition to prevent and reverse protein glycation during oxidative stress in human
BR112019022918B1 (pt) Compostos farmacêuticos contendo selênio para modulação do metabolismo da glicose, composições farmacêuticas e seus usos
Zizi et al. Serelaxin Protects H9c2 Cardiac Myoblasts against Hypoxia and Reoxigenation-Induced Damage by Up-Regulation of AMPK/SIRT1: Further Insight into the Molecular Mechanisms of Cardioprotection of This Hormone
HK40067960A (en) Therapeutic or prophylactic method for diabetes using combination medicine
HK40067738A (en) Oxathiazin compounds for inhibiting gapdh

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40017181

Country of ref document: HK